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Abstract
Stem cell therapy is one of the most promising treatments for the near future. It is expected that
this kind of therapy can ameliorate or even reverse some diseases. With regard to type 1 diabetes,
studies analyzing the therapeutic effects of stem cells in humans began in 2003 in the Hospital das
Clínicas of the Faculty of Medicine of Ribeirão Preto - SP USP, Brazil, and since then other centers
in different countries started to randomize patients in their clinical trials. Herein we summarize
recent data about beta cell regeneration, different ways of immune intervention and what is being
employed in type 1 diabetic patients with regard to stem cell repertoire to promote regeneration
and/or preservation of beta cell mass.
The Diabetes Control and Complications Trial (DCCT) was a 7-year longitudinal study that
demonstrated the importance of the intensive insulin therapy when compared to conventional
treatment in the development of chronic complications in patients with type 1 diabetes mellitus
(T1DM). This study also demonstrated another important issue: there is a reverse relationship
between C-peptide levels (endogenous indicator of insulin secretion) chronic complications - that
is, the higher the C-peptide levels, the lower the incidence of nephropathy, retinopathy and
hypoglycemia. From such data, beta cell preservation has become an additional target in the
management of T1DM [1].
Immune interventions used in type 1 diabetes
Since the identification of the autoimmune etiology of
T1DM in the late 1970s, the use of immunosuppressive
agents began to occur. In 1981, Eliot and colleagues [2]
treated newly diagnosed children with prednisone with
the aim of stopping pancreatic β-cell destruction by the
autoimmune process. Urinary C-peptide levels in the
group treated with corticosteroid were significantly higher
than control for 1 year after therapy was initiated. Subse-
quently, short-term studies were conducted using azathi-
oprine [3], azathioprine plus prednisone [4], and
cyclosporine [5] and demonstrated a slower decline (or
even some improvement) in plasma C-peptide levels. In
those studies, some patients experienced short periods
(<1 year) during which they were free from insulin treat-
ment (Table 1). The chronic toxicity of immunosuppres-
sion and the loss of the metabolic benefits after the
withdrawal of the immunosuppressive agents limited the
routine use of these therapies.
Since 2000, studies have been published on acute immu-
nomodulating therapies that are theoretically aimed at
providing longer immunologic effect. These studies were
performed with heat shock protein [6], anti-thymocyte
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globulin [6], antibody anti-CD3 [7] and glutamic acid
decarboxylase (GAD) [9]. Such studies also showed sev-
eral degrees of beta cell mass preservation; however, none
of the patients became insulin-independent.
At the University of Florida, cell therapy for T1DM was
conducted using autologous umbilical cord blood cells.
Such cells have immunomodulating properties and are
able to secrete cytokines that promote a decrease in the
population of cytotoxic T lymphocytes and increase the
population of regulatory T cells (T-regs), but they do not
have proven regenerative properties. In this kind of ther-
apy, a simple endovenous injection is applied and a study
of this was recently conducted with a group of 21 patients
who were an average of 5 years old and had had diabetes
an average of 9 months, paired with a control group of
patients receiving usual insulin therapy [10]. After a fol-
low-up of 1 year, no significant biological differences were
observed in the C-peptide levels and in the insulin doses
used during that year ([10] and personal communica-
tion).
Another form of cell therapy is that performed by a group
of researchers from Argentina, China and United States
using stem cells from the patient's own bone marrow
(including a conglomerate of mesenchymal stem cells and
hematopoietic stem cells) obtained in a bone marrow
biopsy. While still under anesthetic, these cells are infused
by arterial catheterization directly into the patient's pan-
creas. This therapy was performed in 22 T1DM patients
and in 31 type 2 diabetic patients. The authors did not
publish complete data at all [11].
Brazilian leadership in cell therapy for type 1 
diabetes
By the end of 2003, cell therapy for T1DM started being
performed in humans, and the world's first study was per-
formed by the Divisions of Immunology and Endocrinol-
ogy of the Hospital das Clínicas of the Faculty of Medicine
of Ribeirão Preto - University of São Paulo - Brazil [12,13].
The basic inclusion criteria are age between 12 and 35
years and a diagnosis of T1DM less than 6 weeks prior to
inclusion confirmed by positive serum levels of anti-GAD
antibodies.
In the first stage of the protocol, called mobilization, a
small dose of cyclophosphamide is administered intrave-
nously to mobilize hematopoietic stem cells from the
bone marrow to the peripheral blood. Afterwards, we
apply daily subcutaneous injections of the granulocyte
colony stimulating factor to proliferate circulating stem
cells; these cells are then collected and frozen.
Ten to fifteen days later, we start the second phase, called
the conditioning regimen, in which we use high dose
immunosuppression with intravenous cyclophospha-
mide 200 mg/kg plus intravenous rabbit anti-thymocyte
globulin 4.5 mg/kg with aim of 'turning off' the immune
system, mainly the peripheral T cells that retain immuno-
logic memory. Later, we intravenously re-infuse the previ-
ously collected hematopoietic stem cells, which do not
have immunologic memory, to regenerate a new immune
system that will not attack pancreatic beta cells. This pro-
cedure is called 'immunologic resetting' and although no
beta cells are regenerated, those not yet destroyed are pre-
served. It is important to emphasize that evidence in the
medical literature indicates that hematopoietic stem cells
are unable to be differentiated into beta cells. This is why
we include only newly diagnosed patients - that is,
patients who still have residual beta cell mass to be pre-
served.
Using this procedure, we may maintain or increase the
secretion of endogenous insulin, improving the metabolic
control and obviously the risk of chronic complications.
We emphasize that if we obtain increased C-peptide levels
Table 1: Effect of different immunomodulatory therapies on insulin-free period in patients with newly diagnosed type 1 diabetes 
mellitus
Immunomodulating therapy Treatment length Number of patients free from/
total number of patients
Period free from insulin 
(average)
Prednisone2 12 months (daily use) 4/17 3 months
Prednisone + azathioprine4 12 months (daily use) 10/20 1 week
Azathioprine3 12 months (daily use) 0/24 0
Ciclosporin5 24 months (daily use) 53/122 10 months
Antibody anti-CD36 E.V. application 6 days in a row 0 0
Heat shock protein7 1 S.C. application in time 0, + 1 and 
+ 6 months
00
Anti-thymocyte globulin8 E.V. Applications 4 days in a row 0 0
Glutamic acid decarboxylase9 2 subcutaneous applications with 1-
month interval
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for long periods and keep good glycemic control, we may
offer patients a lower risk of chronic complications from
diabetes, even without suspending insulin therapy.
Up to December 2008, we have performed this procedure
in 23 patients: 17 men and 6 women aged 13 to 31 with
an average body mass index of 19.7 kg/m2, an average gly-
cemia level of 395.6 mg/dl and an average glycosylated
hemoglobin level of 8.4% at the time of diagnosis, and
undergoing anti-GAD treatment ranging from 1.1 to 102
U/ml and using an average dose of 0.4 UI/kg/day soon
before starting the treatment.
All patients are recommended to be on a diet and to exer-
cise regularly within a regimen of intensive insulin ther-
apy and carbohydrate counting to try and achieve the
following goals: pre-prandial glycemia <120 mg/dL, post-
prandial glycemia <140 mg/dL and glycosylated hemo-
globin (HbA1c) <7%.
Patients receive psychological guidance to understand
that they still have T1DM and that they must maintain a
routine of automonitoring of capillary glycemia and car-
bohydrate counting to refrain from food abuse. Compli-
ance with these guidelines is a challenge for the
multidisciplinary team.
Of the 23 patients included, 20 remained free from insu-
lin for some period. Of these, 12 have been continuously
insulin-free since treatment, 8 became transiently insulin-
free and 3 maintained daily insulin doses. In the group of
continuously insulin-free patients, most stopped daily
insulin injections soon after stem cell infusion and the
mean period free from insulin is 31 months (ranging from
14 to 52 months). There was a significant reduction in
HbA1c compared with pretreatment values, with all meas-
ures below 7% during follow-up. In parallel, this group of
patients had important increases in mean peak-stimulated
C-peptide levels (0.8 nmol/L pre-treatment versus 2.9
nmol/L after 3 years; P  < 0.05). Of note, all patients
reported important improvement in their quality of life;
complete data will be published soon. Moreover, this long
period without exogenous insulin use associated with
progressive increases in C-peptide levels in multiple
patients practically rules out the hypothesis of a pro-
longed honeymoon phase in this group.
Eight patients became transiently insulin-free for periods
of 6 to 47 months (mean 17.7 months) However, they
have excellent glucose control using small doses of insu-
lin. Interestingly, in two patients who relapsed after being
insulin free for 43 and 47 months, respectively, we opted
to add sitagliptin (a dipeptidyl peptidase-4 inhibitor) 100
mg per day orally 4 and 2 months after resumption of
insulin treatment. Both became insulin-free again 1 and 2
months later, and have remained free from exogenous
insulin for more than 5 and 6 months, respectively. Peak-
stimulated C-peptide levels declined in both patients
before insulin treatment was resumed; however, C-pep-
tide levels increased again after sitagliptin prescription,
corresponding with the period of insulin-independence.
Aside from this, we believe that suppression of glucagon
levels can also explain the rapid insulin suspension after
sitagliptin use. Additionally, immunomodulating effects
of sitagliptin are speculated. So, this is the first report of
complete insulin suspension in individuals with T1DM
using sitagliptin [14].
In the whole group of eight patients who were transiently
insulin-free, there was a significant increase in C-peptide
levels from 0.6 nmol/L pre-treatment to 1.7 nmol/L 4
years after treatment (P < 0.05). To the best of our knowl-
edge, this is the most prolonged period of C-peptide
increase (up to 4 years) in interventional trials aiming at
beta cell preservation.
Only three patients did not experience any period free
from insulin. One presented with diabetic ketoacidosis at
diagnosis and received glucocorticoids to prevent rabbit
anti-thymocyte globulin reactions, one developed dia-
betic ketoacidosis before enrollment, and one had inad-
vertently received steroids (300 mg hydrocortisone) along
with stem cell infusion. None of them achieved HbA1c
levels less than 7% in spite of progressive increase in daily
insulin doses (>0.8 IU/kg/day).
The majority of the adverse effects related to treatment
were mild, including nausea, vomiting, fever, hyporexia
and alopecia. With regard to severe adverse effects, two
patients presented bilateral nosocomial pneumonia that
completely responded to intravenous broad spectrum
antibiotics; there was no mortality. During long-term fol-
low-up, there was one case each of Graves' disease, tran-
sient hypergonadotropic hypogonadism, and
autoimmune hypothyroidism. Nine patients had post-
transplant hypospermia. Two patients fathered children 2
years after transplant. There was no mortality.
Expansion of global research centers
In 2006, a Chinese group from the University of Naijing
started a protocol similar to the one in Ribeirão Preto,
with the difference that the stem cell infusion was 50%
into the peripheral vein and 50% straight into the pan-
creas through arterial catheterization. Of the five patients
initially treated less than 3 months after diagnosis, four
became insulin-independent (two of them only tran-
siently) and one had a 50% decrease in insulin dose. All
11 patients who had been diagnosed over 3 months
before treatment kept using insulin.Diabetology & Metabolic Syndrome 2009, 1:19 http://www.dmsjournal.com/content/1/1/19
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In August 2008, in Chicago, we started an international
multicentric randomized research protocol project, simi-
lar to that performed in Brazil, to test the effect of 'immu-
nologic resetting' more widely. This study is being
evaluated by the US Food and Drug Administration and
by American research ethics organizations and will com-
mence in 2009 with the collaboration of our team.
Perspectives
Despite the encouraging results obtained so far, we realize
the limitations of our study, such as risk of infections, ele-
vated cost, need of an ultra-specialized team, requirement
for patients to have been diagnosed no later than 6 weeks
prior to treatment, and so on.
Our next step, the use of mesenchymal stem cells, has
already been performed. Therapy with mesenchymal stem
cells plays a very attractive theoretical role: regeneration of
beta cells and immunomodulating action. Thus, its use in
humans would eliminate the use of chemotherapeutic
agents. Studies in vitro using growth factors could differen-
tiate mesenchymal cells and beta cells. These cells in ani-
mal models of T1DM have been able to reverse
hyperglycemia. Stem cells are the largest focus of interest
among diabetologists working with cell therapy around
the world and were a matter of wide debate in the 2008
American Congress of Diabetes in San Francisco.
In 2008, our group of researchers at the Medical School of
Ribeirao Preto - USP started pioneering studies in humans
with T1DM using mesenchymal stem cells. The protocol
includes bone marrow biopsy under general anesthesia in
first-degree relatives for the collection of mesenchymal
cells. These cells are sent to a laboratory to be stimulated
to proliferate for a month and are later infused into the
patient through a gelatinous solution of approximately
100 ml; there is no need for chemotherapy. The patient is
hospitalized for 1 day but only as a precaution. After 1
month, the patient receives another infusion. So far, we
are not yet sure how many infusions will be necessary.
Inclusion criteria are age 12 to 35 years, diagnosis of
T1DM less than 4 weeks prior to treatment without
ketoacidosis and positive serum levels of anti-GAD. So far,
two patients have been included in this protocol and, as
soon as we have a proper follow-up, the results will be
published.
Conclusion
Cell therapy is one of the research fields that have been
widely expanding in the past few years. There is much
expectation around this field, especially with regard to
diabetes mellitus as it is a chronic disease from which
organic and psychosocial data could be derived. We are
not sure if we will obtain a 'cure', but we are glad to know
that Brazilian science is collaborating decisively in the
search for revelatory results.
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